… Background Dabigatran etexilate, a direct oral anticoagulant, may be an effective and safe
alternative for treating acute venous thromboembolism (VTE) in children. Methods This open-…

… Dabigatran etexilate is a prodrug and is metabolized into the active compound dabigatran …
only reversal agent that binds with direct thrombin inhibitor dabigatran to inhibit its effect [44]. …

… in clinical practice. As a new oral reversible thrombin inhibitor, dabigatran etexilate is …
biotransformed into an active form of dabigatran, which directly inhibits thrombin (factor IIa) activity …

… Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor
dabigatran etexilate. Clinical pharmacokinetics, 2008; 47(5): 285-95. 15. Van Ryn J, Stangier J, …

… , a thrombin inhibitor and P-gp substrate, making dabigatran exposure an intestinal P-gp
activity indicator. This study (NCT02568397) was conducted in 60 healthy subjects receiving a …

… Dabigatran etexilate (DABE) is a direct oral anticoagulant (DOAC) and may be combined
with ticagrelor, a P2Y 12 inhibitor with antiplatelet effects. This combination of antiplatelet drugs …

… The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new
oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303…

… A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for
prevention of thromboembolic events following total hip or knee replacement: the BISTRO II …

… Dabigatran etexilate is effectively and completely converted to … Clinical pharmacokinetics
and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug …

… dabigatran, a direct thrombin inhibitor and 4 direct factor Xa … a direct thrombin inhibitor and
4 direct factor Xa inhibitors (… , doses, pharmacodynamic, and pharmacokinetic characteristics […